NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 04:00PM ET
3.46
Dollar change
-0.02
Percentage change
-0.57
%
Index- P/E- EPS (ttm)-13.14 Insider Own0.00% Shs Outstand0.54M Perf Week-10.59%
Market Cap3.00M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-5.72%
Enterprise Value2.13M PEG- EPS next Q- Inst Own2.78% Short Float- Perf Quarter8.87%
Income-5.24M P/S- EPS this Y- Inst Trans- Short Ratio0.02 Perf Half Y-53.99%
Sales0.00M P/B- EPS next Y- ROA-293.85% Short Interest0.03M Perf YTD-49.56%
Book/sh-0.16 P/C3.45 EPS next 5Y- ROE-512.79% 52W High15.54 -77.73% Perf Year-72.69%
Cash/sh1.00 P/FCF- EPS past 3/5Y2.78% -10.56% ROIC- 52W Low2.35 47.23% Perf 3Y-91.88%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility6.60% 7.41% Perf 5Y-99.20%
Dividend TTM- EV/Sales- EPS Y/Y TTM31.66% Oper. Margin- ATR (14)0.45 Perf 10Y-100.00%
Dividend Ex-Date- Quick Ratio0.86 Sales Y/Y TTM- Profit Margin- RSI (14)45.82 Recom-
Dividend Gr. 3/5Y- - Current Ratio0.86 EPS Q/Q49.43% SMA20-2.75% Beta- Target Price-
Payout- Debt/Eq- Sales Q/Q- SMA50-8.50% Rel Volume0.07 Prev Close3.48
Employees3 LT Debt/Eq- Earnings- SMA200-40.51% Avg Volume2.09M Price3.46
IPODec 18, 1996 Option/ShortNo / Yes EPS/Sales Surpr.- - Trades Volume140,794 Change-0.57%
May-29-25 02:40PM
May-21-25 09:15AM
May-19-25 07:43AM
May-10-25 11:55AM
Apr-29-25 04:00PM
08:12AM Loading…
Nov-05-24 08:12AM
Oct-29-24 10:27AM
Jun-25-24 06:53AM
May-22-24 08:12AM
May-01-24 08:38AM
Apr-17-24 08:42AM
Apr-01-24 09:53PM
04:20PM
Mar-27-24 08:42AM
Mar-25-24 05:00PM
08:41AM Loading…
Mar-21-24 08:41AM
Feb-13-24 08:30AM
Dec-12-23 07:30AM
Oct-13-23 09:00AM
Sep-26-23 08:18AM
Mar-22-23 12:55PM
Apr-26-22 08:15AM
Nov-16-21 09:58AM
Aug-30-21 09:15AM
Aug-17-21 07:45AM
Jul-23-21 04:21PM
Jul-08-21 11:20AM
Jul-06-21 06:17AM
Jun-23-21 09:35AM
Jun-16-21 09:15AM
03:06PM Loading…
Apr-29-21 03:06PM
Apr-26-21 08:58PM
Dec-16-20 09:15AM
Sep-08-20 12:10PM
Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.